A Phase 2 interventional study of Alcohol (IV) and Saline (0.9%, sterile, for infusion) in Alcohol Use, Chronic Low-back Pain (cLBP) and Alcohol Use Disorder (AUD), sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Yale University · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Alcohol's effects on pain are biphasic and depend on blood alcohol concentration; as concentration rises (i.e., ascending limb) and then falls (i.e., descending limb), alcohol produces distinct, time-dependent effects on pain. However, the biphasic effects of alcohol among individuals with chronic pain and alcohol use disorder, and the extent to which these effects may motivate alcohol consumption, remain poorly understood. The primary objective of the proposed study is to quantify alcohol-clamp-induced group differences in the net effects of alcohol on pain threshold and tolerance.
Alcohol use disorder (AUD) and chronic pain (CP) are major public health challenges in the United States. AUD is the third leading preventable cause of death, and CP affects up to 116 million Americans. Chronic low back pain alone is the leading global cause of disability. Together, these conditions impose an economic burden exceeding $750 billion annually. People with AUD are significantly more likely to experience moderate to severe pain (43-75% vs. 18% in the general population), and unrelieved pain can worsen alcohol craving and increase use of analgesics that carry addiction risk, such as opioids.
The relationship between AUD and CP operates as a self-reinforcing cycle, where individuals use alcohol for pain relief but overtime develop a tolerance to its effects, requiring increasing amounts to achieve the same analgesic effects. Subsequently, when alcohol use is reduced or stopped, withdrawal-driven hyperalgesia emerges, further increasing pain sensitivity. This creates a negative reinforcement trap: individuals drink not primarily for the initial euphoria or analgesia, but to escape the rebound pain that alcohol itself has exacerbated. Over time, this cycle alters nociceptive processing, leading to heightened pain sensitivity, impaired pain inhibition, and greater alcohol craving. Consistent with negative-reinforcement models, 72% of individuals with AUD report drinking for pain relief at least sometimes, and 42.4% at least half the time.
Despite their frequent co-occurrence, research has largely examined AUD and CP separately. Prior work that was done in healthy persons, rather than in persons with AUD, had limited control of exposure due to the high variability in oral alcohol pharmacokinetics, and missed alcohol-comorbidity interactions. This study addresses these gaps by enrolling persons with AUD, CP, and AUD+CP alongside healthy controls, using a computer-controlled IV alcohol clamp to eliminate pharmacokinetic variability to rigorously examine the pain-alcohol relationship.
702 studies on the registry are indexed under Alcohol Drinking; 134 are open to participants now.
This study's planned enrollment of 132 is close to the median of 124 across 608 interventional studies indexed under Alcohol Drinking.
Browse Alcohol Drinking studies →Yale University is the lead sponsor of 1,773 studies on the registry; 297 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Compared within Alcohol Drinking, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For AUD groups (encompassing persons with AUD-only and persons with AUD+CP):
For CP groups (encompassing persons with CP-only and persons with AUD+CP):
- 1. Have high-impact, non-cancer low back pain that has persisted for at least three months, occurs on most days, and limits life or work activities.
For healthy individuals:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants whose alcohol use falls within normal NIAAA defined limits and do not experience chronic low back pain.
Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)
Participants meeting DSM-5 criteria for alcohol use disorder who do not experience chronic low back pain.
Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)
Participants who have high-impact, non-cancer low back pain that has persisted for at least three months whose alcohol use falls within normal NIAAA defined limits.
Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)
Participants meeting DSM-5 criteria for AUD and experience high-impact, non-cancer low back pain that has persisted for at least three months.
Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)
Two 1 liter IV bags containing 6% alcohol will be administered to participants to achieve 0.1 BrAC.
The placebo will consist of saline, administered intravenously using the same IV bags, infusion equipment, and procedures as the alcohol.
Net effect of alcohol on heat pain threshold (HPTh), compared across four diagnostic groups
Heat pain threshold (HPTh) is the temperature (°C) at which a heat stimulus first becomes painful. Scores are baseline-adjusted alcohol-minus-placebo differences in HPTh. Net effect = ascending-limb increase minus descending-limb decrease. Ascending-limb increase: the maximum rise in HPTh from baseline to BrAC 0.10 g/dL. Descending-limb decrease: the maximum drop in HPTh from BrAC 0.10 g/dL to 0.02 g/dL. Positive values indicate net analgesia; negative values indicate net hyperalgesia. Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Net effect of alcohol on heat pain tolerance (HPTol), compared across four diagnostic groups
Heat pain tolerance (HPTol) is the highest temperature (°C) the participant tolerates, measured right after HPTh. Scores are baseline-adjusted alcohol-minus-placebo differences in HPTol. Net effect = ascending-limb increase minus descending-limb decrease. Ascending-limb increase: the maximum rise in HPTol from baseline to BrAC 0.10 g/dL. Descending-limb decrease: the maximum drop in HPTol from BrAC 0.10 g/dL to 0.02 g/dL. Positive values indicate net analgesia; negative values indicate net hyperalgesia. Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Mapping pain modulatory mechanisms of the transition from analgesia to hyperalgesia as measured by Conditioned Pain Modulation (CPM)
CPM will serve as an index of descending pain inhibition, measured as the reduction in pain perception to a test stimulus when delivered simultaneously with a conditioning stimulus. Seven heat stimuli (46.5°C, 4 sec duration, 15-sec inter-stimulus interval) will be delivered to the dominant-hand thenar eminence. During the heat stimuli, a contralateral conditioning cold stimulus (5°C for 40 sec) will be applied to the ventral forearm. Participants will continuously rate pain on a 0 to 100 mm computerized visual analog scale (Co-VAS), where higher ratings mean more pain. CPM will be defined as the peak unconditioned minus the peak conditioned Co-VAS pain rating (i.e., the maximum rating to the heat test stimuli without versus with cold conditioning), with higher values indicating stronger descending inhibition. CPM ranges from minus 100 to 100; higher is better. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Mapping pain modulatory mechanisms of the transition from analgesia to hyperalgesia as measured by Temporal Summation of Pain (TSP)
TSP will serve as an index of pain facilitation, reflecting the wind-up of pain perception in response to repeated noxious stimuli. Ten heat pulses (46.5°C, 0.5-sec duration, 2.5-sec inter-pulse interval) will be delivered while participants continuously rate their pain on a 0 to 100 mm computerized visual analog scale (Co-VAS), where higher ratings mean more pain. TSP will be quantified as the area under the curve (AUC) of the Co-VAS ratings across the 10 pulses, with higher values indicating greater wind-up of pain. The lowest possible value is 0; higher values mean a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Change in baseline expectancy as assessed by the Expectancy of Alcohol Analgesia (EAA) questionnaire
The Expectancy of Alcohol Analgesia (EAA) questionnaire is a validated 5-item self-report scale designed to measure an individual's belief or expectation that drinking alcohol will reduce or help them cope with physical pain. Each item is rated on a 10-point scale ranging from 0 ('completely/extremely unlikely') to 9 ('completely/extremely likely'). Scores are calculated by summing the ratings of each item, with higher scores reflecting stronger expectancies. Total scores range from 0 to 45; higher scores are neither a better nor a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Perceived pain relief of alcohol administration as assessed by a 100-mm visual analog scale (VAS)
Perceived pain relief will be assessed at each BrAC window with a single 100-mm visual analog scale (VAS) (anchors "no pain relief" to "complete pain relief"). Scores range from 0 to 100; higher scores mean more pain relief (a better outcome). Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Alcohol-induced changes in pro- and anti-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta, IL-10) versus placebo
To investigate peripheral neuroimmune mechanisms underlying alcohol's effects venous blood samples will be collected at three BrAC matched windows. Pro-inflammatory (IL-6, TNF-α, IL-1β) and anti-inflammatory (IL-10) cytokines will be assayed in duplicate using multiplex immunoassay panels for Ella (Bio-Techne). Duplicates are averaged and intra/inter-assay coefficient of variation is set at less than 10%. These cytokines were selected as they are elevated in both CP and AUD and show rapid changes in response to alcohol exposure. All four are reported in picograms per milliliter (pg/mL). Higher values of IL-6, TNF-α and IL-1β mean more inflammation; higher IL-10 means more anti-inflammatory activity. Measured at baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.02 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Alcohol-induced sedation as assessed by a 100-mm visual analog scale (VAS)
Alcohol-induced sedation will be assessed at each BrAC window with a single 100-mm visual analog scale (VAS) (anchors "not at all sedated" to "extremely sedated"). Scores range from 0 to 100; higher scores mean more sedation (a worse outcome). Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Alcohol-related affect as assessed by the Brief Biphasic Alcohol Effects Scale (B-BAES) stimulation subscale
The Brief Biphasic Alcohol Effects Scale (B-BAES) is a self-report questionnaire assessing the acute stimulant and sedative properties of alcohol across the ascending and descending BrAC phases. For this study only the stimulation subscale will be assessed. The stimulation subscale includes 3 items measuring activation, arousal, and positive-like activation. Higher scores indicate stronger feelings of reward, sociability, and euphoria while BrAC is rising. Each item is rated on an 11-point scale ranging from 0 ('Not at all') to 10 ('Extremely'). The subscale score is calculated by summing the ratings of the respective items. Subscale scores range from 0 to 30; higher scores are neither a better nor a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Alcohol related craving as assessed by the Alcohol Urge Questionnaire (AUQ)
The Alcohol Urge Questionnaire (AUQ) is an 8-item self-report questionnaire designed to measure a person's acute, real-time desire or urge to drink alcohol ("right now"). Each item is rated on a 7-point Likert scale ranging from 1 ("strongly disagree") to 7 ("strongly agree"). Scores are calculated by summing the ratings of each item, with higher scores reflecting a stronger, more acute urge to consume alcohol. Total scores range from 8 to 56; higher scores mean a worse outcome. Measured at three BrAC windows in each session (baseline 0.00 g/dL, rising 0.10 g/dL and falling 0.04 g/dL) and at discharge (BrAC below 0.02 g/dL).
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion
Alcohol-induced cognitive/psychomotor impairment as measured by a computerized Simple Reaction Time (SRT)
A computerized Simple Reaction Time (SRT) test will measure the exact time it takes for a participant to detect a single, predictable stimulus (a star on the screen) and execute a single, predetermined physical response (pressing a mouse button). The primary outcome will be speed (milliseconds). Lower values mean faster responses (a better outcome). Measured at two BrAC windows in each session: baseline (0.00 g/dL) and rising 0.10 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 2 hours after the start of the infusion
Alcohol-induced cognitive/psychomotor impairment as measured by a computerized Digit Symbol Substitution Test (DSST)
The computerized Digit Symbol Substitution Test (DSST) is a brief timed coding task (90 to 120 seconds) in which participants use a key to pair digits with symbols and produce as many correct matches as possible. The primary outcome of the DSST is the amount of correctly matched symbols and the speed at which matches are made. More correct matches and faster matching mean better performance (a better outcome). Measured at two BrAC windows in each session: baseline (0.00 g/dL) and rising 0.10 g/dL.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 2 hours after the start of the infusion
Monitoring safety and Adverse Events (AEs) measured by the Systematic Assessment for Treatment Emergent Events (SAFTEE)
The Systematic Assessment for Treatment Emergent Events (SAFTEE) multi-symptom checklist that has been used successfully in the investigators previous studies to assess and monitor any adverse events and possible side effects of study medications. It includes information regarding the severity of any presenting symptoms (0= none, 1= mild, 2= moderate, and 3= severe), as well as the course of action taken by the study staff in response. Any AEs observed by study staff and/or spontaneously reported by the participant will be continuously monitored throughout their enrollment however documentation on the SAFTEE will be completed at four discrete timepoints per test session: pre-infusion, ascending 0.10 g/dL, descending 0.04 g/dL, and pre-discharge (BrAC less than 0.02 g/dL) as well as during the one-week follow-up. Outcomes will be tabulated, and descriptive analyses will be conducted. Dosing conditions will be compared with regards to the frequency and severity of AEs.
Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the infusion; One-week follow-up
Alcohol withdrawal symptoms will be assessed using the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)
The Clinical Institute Withdrawal Assessment Alcohol Scale Revised (CIWA-AR) is a 10-item instrument used to assess the severity of alcohol withdrawal. Nine items are scored on a 0 to 7 scale while one item (orientation) is rated from 0 to 4. Scores are calculated by summing the ratings of each item with total scores ranging from 0 to 67, with higher scores indicating more severe withdrawal.
Time frame: Screening; Each of two test sessions: pre-infusion, BrAC less than 0.02 g/dL (pre-discharge); one-week follow-up
Monitoring cardiovascular effects
To monitor cardiovascular effects vital signs including heart rate and blood pressure will be measured at screening, during the infusion sessions starting at pre-infusion and every 30 minutes until discharge (approximately 6 hours), and during the one-week follow-up to monitor for acute changes.
Time frame: Screening, Two test sessions [up to 6 hours each], one-week follow-up
Plan to share: No
Start is estimated for Feb 2027; primary completion for Apr 2031, 50 months later.
Of 24 phase 2 interventional studies under Alcohol Drinking, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.